Current Edition:
|
Table of Contents
| |
 |
Is sentinel node biopsy the standard of care? |
| |
Parenchymal versus intradermal tracer injections for sentinel node biopsy |
| |
Intraoperative radiation therapy |
| |
Evaluating results of the ATAC adjuvant trial in postmenopausal women |
| |
Future trials of aromatase inhibitors in DCIS |
| |
|
| J Michael Dixon, FRCS |
|
Background of ATAC Trial: Anastrozole vs Tamoxifen vs Combination |
| |
Toxicity profile of anastrozole versus tamoxifen |
| |
Other aromatase inhibitors as adjuvant therapy |
| |
Anastrozole in chemoprevention trials |
| |
|
|
| S Eva Singletary, MD |
|
Breast Cancer Risk assessment in clinical practice |
| |
The role of ductal lavage in a clinical risk management strategy |
| |
Relationship between atypical cytology and atypical ductal hyperplasia |
| |
Incorporating the ATAC outcomes into clinical practice |
| |
|
|
| |
|
|
|
|
|
|
